DefinePK

Abstract

Newer development in endocrine pharmacology haveblurred the distinction between biosimilars and generics.The originator semaglutide, for example, is a biologicallyactive compound, but later versions are chemicallysynthesized generics. Tirzepatide is a syntheticpolypeptide. These molecules are marketed in differentstrengths and delivery devices across the world. The word‘pharmaco-similar’ can be used to describe bothbiosimilar and generic versions of originator peptidebasedmedications. This communication suggests auseful framework which assists in sharing informationand reaching an informed decision regarding choice ofanti-obesity medication. This approval process and status,evidence and experience base, economic factors, rulesrelated to interchange/substitution, robustness of coldchain, and availability of uninterrupted supply allinfluence this decision.Keywords: Biosimilar, diabetes, generic, GIPRA, GLP1RA,liraglutide, obesity, semaglutide, tirzepatide